Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19292918 | 0.77 | — | — | |
| SCHEMBL16868384 | 0.76 | ADRA2B (0.59) | — | |
| SCHEMBL16865696 | 0.73 | — | — | |
| SCHEMBL16865695 | 0.72 | MEN1 (0.50) | MEN1POLBKMT2A | |
| SCHEMBL18195192 | 0.62 | ALDH1A1 (0.35) | MEN1POLBKMT2A | |
| SCHEMBL24568398 | 0.58 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL14514785 | 0.57 | — | — | |
| SCHEMBL18591636 | 0.57 | — | — | |
| SCHEMBL256062 | 0.55 | — | — | |
| SCHEMBL5539788 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159477-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | GEISTLICH PHARMA AG (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159477-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | GEISTLICH PHARMA AG (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-4011871-A2 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | Geistlich Pharma AG (CH) | 2022-06-15 | — | — | EP | disclosed |
| EP-3233813-B1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | GEISTLICH PHARMA AG (CH) | 2022-02-02 | — | — | EP | disclosed |
| US-20210163432-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | GEISTLICH PHARMA AG (CH) | 2021-06-03 | — | — | US | disclosed |
| US-10968190-B2 | Processes for preparing oxathiazin-like compounds | GEISTLICH PHARMA AG (CH) | 2021-04-06 | — | — | US | disclosed |
| US-10736902-B2 | Method of treating triple negative breast cancer | GEISTLICH PHARMA AG (CH) | 2020-08-11 | — | — | US | disclosed |
| US-10392355-B2 | Processes for preparing oxathiazin-like compounds | GEISTLICH PHARMA AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20190091233-A1 | METHOD OF TREATING TRIPLE NEGATIVE BREAST CANCER | GEISTLICH PHARMA AG (CH) | 2019-03-28 | — | — | US | disclosed |
| US-9844555-B2 | Oxathiazine derivatives as antibacterial and anticancer agents | GEISTLICH PHARMA AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-20170196876-A1 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS | GEISTLICH PHARMA AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-9624187-B2 | Oxathiazine derivatives as antibacterial and anticancer agents | GEISTLICH PHARMA AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624187-B2 | Oxathiazine derivatives as antibacterial and anticancer agents | GEISTLICH PHARMA AG (CH) | 2017-04-18 | — | — | US | disclosed |
| WO-2016098054-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | GEISTLICH PHARMA AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160159759-A1 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS | GEISTLICH PHARMA AG (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160159759-A1 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS | GEISTLICH PHARMA AG (CH) | 2016-06-09 | — | — | US | disclosed |
| US-9241943-B2 | Oxathiazine derivatives as antibacterial and anticancer agents | GEISTLICH PHARMA AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9241943-B2 | Oxathiazine derivatives as antibacterial and anticancer agents | GEISTLICH PHARMA AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150182534-A1 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS | GEISTLICH PHARMA AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150182534-A1 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS | GEISTLICH PHARMA AG (CH) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736902-B2 | Method of treating triple negative breast cancer | IL2, TTBK2, TOP2A | MEN1 3955/4885POLB 1469/4885KMT2A 624/4885 |
| US-20150182534-A1 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS | OXA1L, TOP2A, HELZ | MEN1 3082/4885POLB 1312/4885KMT2A 1998/4885 |
| US-20230159477-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | OXA1L, MAPT, OTC | MEN1 1059/4885POLB 110/4885KMT2A 3018/4885 |
| US-10392355-B2 | Processes for preparing oxathiazin-like compounds | OXA1L, MAPT, OTC | MEN1 1059/4885POLB 110/4885KMT2A 3018/4885 |
| US-10968190-B2 | Processes for preparing oxathiazin-like compounds | DCXR, SORD, ADH1C | MEN1 4659/4885POLB 916/4885KMT2A 4252/4885 |
| US-20170196876-A1 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS | TOP2A, OXA1L, TOP1 | MEN1 3155/4885POLB 580/4885KMT2A 2479/4885 |
| US-20210163432-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | OXA1L, MAPT, OTC | MEN1 1059/4885POLB 110/4885KMT2A 3018/4885 |
| US-20160159759-A1 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS | TOP2A, OXA1L, TOP1 | MEN1 3155/4885POLB 580/4885KMT2A 2479/4885 |
| US-20190091233-A1 | METHOD OF TREATING TRIPLE NEGATIVE BREAST CANCER | IL2, TTBK2, TOP2A | MEN1 3955/4885POLB 1469/4885KMT2A 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.